PsyRx CNS Bio-Tech (XTAE:PSRX) Interest Coverage: 0 (At Loss) (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:PSRX PsyRx CNS Bio-Tech Ltd XTAE:PSRX
10 GF Score
Price ₪0.73
! 1 Warning Sign
View Full Analysis

What is PsyRx CNS Bio-Tech Interest Coverage?

PsyRx CNS Bio-Tech XTAE:PSRX +3.09% 10 Interest Coverage is 0 (At Loss) as of . 20. GuruFocus rates XTAE:PSRX with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 684 Drug Manufacturers companies, PsyRx CNS Bio-Tech ranks worse than 146198.68% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. PsyRx CNS Bio-Tech's Operating Income for the six months ended in . 20 was ₪0.00 Mil. PsyRx CNS Bio-Tech's Interest Expense for the six months ended in . 20 was ₪0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for PsyRx CNS Bio-Tech's Interest Coverage or its related term are showing as below:


XTAE:PSRX's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.725
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


PsyRx CNS Bio-Tech  (XTAE:PSRX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


PsyRx CNS Bio-Tech Interest Coverage Related Terms


PsyRx CNS Bio-Tech Interest Coverage Historical Data

* Premium members only.

The historical data trend for PsyRx CNS Bio-Tech's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

PsyRx CNS Bio-Tech Interest Coverage Chart

PsyRx CNS Bio-Tech Annual Data
Trend
Interest Coverage

PsyRx CNS Bio-Tech Semi-Annual Data
Interest Coverage

XTAE:PSRX vs ZTS, UTHR, VTRS: Interest Coverage Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PsyRx CNS Bio-Tech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PsyRx CNS Bio-Tech Interest Coverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PsyRx CNS Bio-Tech's Interest Coverage distribution charts can be found below:

* The bar in red indicates where PsyRx CNS Bio-Tech's Interest Coverage falls into.


XTAE:PSRX
10GF Score
PsyRx CNS Bio-Tech Ltd XTAE:PSRX
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PsyRx CNS Bio-Tech Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PsyRx CNS Bio-Tech's Interest Coverage for the fiscal year that ended in . 20 is calculated as

Here, for the fiscal year that ended in . 20, PsyRx CNS Bio-Tech's Interest Expense was ₪0.00 Mil. Its Operating Income was ₪0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was ₪0.00 Mil.

PsyRx CNS Bio-Tech had no debt (1).

PsyRx CNS Bio-Tech's Interest Coverage for the quarter that ended in . 20 is calculated as

Here, for the six months ended in . 20, PsyRx CNS Bio-Tech's Interest Expense was ₪0.00 Mil. Its Operating Income was ₪0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was ₪0.00 Mil.

PsyRx CNS Bio-Tech had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
PsyRx CNS Bio-Tech (XTAE:PSRX) has a Interest Coverage of 0 (At Loss) as of . 20. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PsyRx CNS Bio-Tech and its competitors. According to the industry distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 684 companies in the Drug Manufacturers industry.
Is PsyRx CNS Bio-Tech's Interest Coverage too high?
PsyRx CNS Bio-Tech's current Interest Coverage is 0 (At Loss). Based on the distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PsyRx CNS Bio-Tech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does PsyRx CNS Bio-Tech's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 684 companies for Interest Coverage. This places PsyRx CNS Bio-Tech in the lower half of its industry. The industry median Interest Coverage is 12.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on PsyRx CNS Bio-Tech and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PsyRx CNS Bio-Tech's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyRx CNS Bio-Tech stock overvalued right now?
PsyRx CNS Bio-Tech (XTAE:PSRX) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). PsyRx CNS Bio-Tech's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For PsyRx CNS Bio-Tech (XTAE:PSRX), the current Interest Coverage is 0 (At Loss) as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PsyRx CNS Bio-Tech Business Description

Address Arik Einstein 3, Herzliya, ISR, 4610301
PsyRx CNS Bio-Tech Ltd Formerly Cannabotech Ltd is engaged in the research and development of cannabis-based drugs. It is a biomedical company focused on the benefits of cannabinoids and medicinal mushrooms, applying the pure power of nature and science to health issues.
10GF Score

Get the complete analysis for XTAE:PSRX

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.73
Price